Literature DB >> 19544460

Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging.

Hui Wang1, Feng Cao, Abhijit De, Yuan Cao, Christopher Contag, Sanjiv S Gambhir, Joseph C Wu, Xiaoyuan Chen.   

Abstract

The objective of the study was to track the distribution and differentiation of mesenchymal stem cells (MSCs) in tumor-bearing mice. The 4T1 murine breast cancer cells were labeled with renilla luciferase-monomeric red fluorescence protein (rLuc-mRFP) reporter gene. The MSCs labeled with firefly luciferase-enhanced green fluorescence protein (fLuc-eGFP) reporter gene (MSCs-R) were isolated from L2G85 transgenic mice that constitutively express fLuc-eGFP reporter gene. To study the tumor tropism of MSCs, we established both subcutaneous and lung metastasis models. In lung metastasis tumor mice, we injected MSCs-R intravenously either on the same day or 4 days after 4T1 tumor cell injection. In subcutaneous tumor mice, we injected MSCs-R intravenously 7 days after subcutaneous 4T1 tumor inoculation. The tumor growth was monitored by rLuc bioluminescence imaging (BLI). The fate of MSCs-R was monitored by fLuc BLI. The localization of MSCs-R in tumors was examined histologically. The osteogenic and adipogenic differentiation of MSCs-R was investigated by alizarin red S and oil red O staining, respectively. The mechanism of the dissimilar differentiation potential of MSCs-R under different tumor microenvironments was investigated. We found that the 4T1 cells were successfully labeled with rLuc-mRFP. The MSCs-R isolated from L2G85 transgenic mice constitutively express fLuc-eGFP reporter gene. When injected intravenously, MSCs-R survived, proliferated, and differentiated in tumor sites but not elsewhere. The localization of GFP(+) MSCs-R in tumor lesions was confirmed ex vivo. In conclusion, the MSCs-R can selectively localize, survive, and proliferate in both subcutaneous tumor and lung metastasis as evidenced by noninvasive bioluminescence imaging and ex vivo validation. The MSCs-R migrated to lung tumor differentiated into osteoblasts, whereas the MSCs-R targeting subcutaneous tumor differentiated into adipocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544460      PMCID: PMC4161123          DOI: 10.1002/stem.81

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  54 in total

1.  Shifting foci of hematopoiesis during reconstitution from single stem cells.

Authors:  Yu-An Cao; Amy J Wagers; Andreas Beilhack; Joan Dusich; Michael H Bachmann; Robert S Negrin; Irving L Weissman; Christopher H Contag
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

2.  Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms.

Authors:  T Kinnaird; E Stabile; M S Burnett; C W Lee; S Barr; S Fuchs; S E Epstein
Journal:  Circ Res       Date:  2004-01-22       Impact factor: 17.367

3.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

4.  Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model.

Authors:  Abdulaziz Al-Khaldi; Hilal Al-Sabti; Jacques Galipeau; Kevin Lachapelle
Journal:  Ann Thorac Surg       Date:  2003-01       Impact factor: 4.330

5.  Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals.

Authors:  Farida Djouad; Pascale Plence; Claire Bony; Philippe Tropel; Florence Apparailly; Jacques Sany; Danièle Noël; Christian Jorgensen
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

Review 6.  Mesenchymal stem cell: use and perspectives.

Authors:  Angelo Tocci; Laura Forte
Journal:  Hematol J       Date:  2003

Review 7.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962

8.  Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms.

Authors:  T Kinnaird; E Stabile; M S Burnett; M Shou; C W Lee; S Barr; S Fuchs; S E Epstein
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

9.  Nonmyeloablative allogeneic bone marrow transplantation for treatment of childhood overlap syndrome and small vessel vasculitis.

Authors:  O Y Jones; R A Good; R A Cahill
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

10.  Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.

Authors:  Andrea Mohr; Mark Lyons; Laura Deedigan; Tina Harte; Georgina Shaw; Linda Howard; Frank Barry; Tim O'Brien; Ralf Zwacka
Journal:  J Cell Mol Med       Date:  2008-03-28       Impact factor: 5.310

View more
  89 in total

1.  A water-soluble coelenterazine for sensitive in vivo imaging of coelenterate luciferases.

Authors:  Danielle Morse; Bakhos A Tannous
Journal:  Mol Ther       Date:  2012-04       Impact factor: 11.454

Review 2.  In vivo imaging in cancer.

Authors:  John Condeelis; Ralph Weissleder
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-09-22       Impact factor: 10.005

3.  Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.

Authors:  Jaime F Modiano; Beth A Lindborg; Ron T McElmurry; Mitzi Lewellen; Colleen L Forster; Edward A Zamora; Jerome Schaack; Donald Bellgrau; Timothy D O'Brien; Jakub Tolar
Journal:  Cancer Immunol Immunother       Date:  2015-08-07       Impact factor: 6.968

4.  Mesenchymal stem cell therapy: Two steps forward, one step back.

Authors:  James Ankrum; Jeffrey M Karp
Journal:  Trends Mol Med       Date:  2010-03-23       Impact factor: 11.951

5.  Dual Reporter Bioluminescence Imaging with NanoLuc and Firefly Luciferase.

Authors:  Anne E Gibbons; Kathryn E Luker; Gary D Luker
Journal:  Methods Mol Biol       Date:  2018

6.  In vivo bioluminescence imaging of hyperglycemia exacerbating stem cells on choroidal neovascularization in mice.

Authors:  Xiang Gao; Yu Wang; Hui-Yuan Hou; Yang Lyu; Hai-Yan Wang; Li-Bo Yao; Jian Zhang; Feng Cao; Yu-Sheng Wang
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

7.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

8.  Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer.

Authors:  Roisin M Dwyer; James Ryan; Ronan J Havelin; John C Morris; Brian W Miller; Zhonglin Liu; Richard Flavin; Cathal O'Flatharta; Mark J Foley; Harrison H Barrett; J Mary Murphy; Frank P Barry; Timothy O'Brien; Michael J Kerin
Journal:  Stem Cells       Date:  2011-07       Impact factor: 6.277

Review 9.  In vivo cell tracking with bioluminescence imaging.

Authors:  Jung Eun Kim; Senthilkumar Kalimuthu; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2014-11-26

10.  Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery.

Authors:  Xinglu Huang; Fan Zhang; Hui Wang; Gang Niu; Ki Young Choi; Magdalena Swierczewska; Guofeng Zhang; Haokao Gao; Zhe Wang; Lei Zhu; Hak Soo Choi; Seulki Lee; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2012-12-08       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.